MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN

doi:10.18632/oncotarget.13022

	MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN
	Xue, Xinying 1,2; Liu, Yuxia 3; Wang, Yong 1; Meng, Mingming 4; Wang, Kaifei 2; Zang, Xuefeng 5; Zhao, Sheng 6; Sun, Xiaohua 7,8; Cui, Lei 9; Pan, Lei 1; Liu, Sanhong10
	2016-12-20
发表期刊	ONCOTARGET
ISSN	1949-2553
卷号	7 期号:51 页码:84508-84519
发表状态	已发表
DOI	10.18632/oncotarget.13022
摘要	Lung cancer remains the leading cause of cancer-associated death worldwide. MiR-21 and miR-155 are the most amplified miRNAs in non-small cell lung carcinoma (NSCLC), and are critical promoters of NSCLC progression. However, it remains unclear how miR-21 and miR-155 induce cancer progression, and whether these miRNAs share common targets, such as tumor suppressor genes required to prevent NSCLC. Here we report that miR-21 and miR-155 levels are elevated in NSCLC and are proportional to the progression of the disease. In addition, miR-21 and miR-155 share nearly 30% of their predicted target genes, including SOCS1, SOCS6, and PTEN, three tumor suppressor genes often silenced in NSCLC. Consequently, antagonizing miR-21, miR-155 or both potently inhibited tumor progression in xenografted animal models of NSCLC. Treatment with miR-21 and miR-155 inhibitors in combination was always more effective against NSCLC than treatment with a single inhibitor. Furthermore, levels of miR-21 and miR-155 expression correlated inversely with overall and disease-free survival of NSCLC patients. Our findings reveal that miR-21 and miR-155 promote the development of NSCLC, in part by downregulating SOCS1, SOCS6, and PTEN. Combined inhibition of miR-21 and miR-155 could improve the treatment of NSCLC.
关键词	non-small cell lung carcinoma miR-21 miR-155 SOCS1 SOCS6
收录类别	SCI
语种	英语
WOS研究方向	Oncology ; Cell Biology
WOS类目	Oncology ; Cell Biology
WOS记录号	WOS:000391353200058
出版者	IMPACT JOURNALS LLC
WOS关键词	TARGETING PTEN ; ACQUIRED-RESISTANCE ; GROWTH ; EXPRESSION ; PATHWAY ; GENE
原始文献类型	Article
引用统计
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/1597
专题	免疫化学研究所_特聘教授组_干细胞生物学实验室
通讯作者	Cui, Lei; Pan, Lei; Liu, Sanhong
作者单位	1.Capital Med Univ, Beijing Shijitan Hosp, Dept Special Med Treatment Resp Dis, Beijing, Peoples R China 2.Chinese Peoples Liberat Army Gen Hosp, Dept Resp Dis, Beijing, Peoples R China 3.Peking Union Med Collage Hosp, Dept Res, Beijing, Peoples R China 4.Capital Med Univ, Beijing Shijitan Hosp, Dept Gastroenterol, Beijing, Peoples R China 5.Capital Med Univ, Beijing Shijitan Hosp, Dept Intens Care Unit, Beijing, Peoples R China 6.Peking Univ, Beijing Shijitan Hosp, Ninth Sch Clin Med, Dept Cardiol, Beijing, Peoples R China 7.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China 8.Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China 9.Capital Med Univ, Beijing Shijitan Hosp, Dept Cent Lab, Beijing, Peoples R China 10.ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China
通讯作者单位	免疫化学研究所
推荐引用方式 GB/T 7714	Xue, Xinying,Liu, Yuxia,Wang, Yong,et al. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN[J]. ONCOTARGET,2016,7(51):84508-84519.
APA	Xue, Xinying.,Liu, Yuxia.,Wang, Yong.,Meng, Mingming.,Wang, Kaifei.,...&Liu, Sanhong.(2016).MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN.ONCOTARGET,7(51),84508-84519.
MLA	Xue, Xinying,et al."MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN".ONCOTARGET 7.51(2016):84508-84519.